| Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus |
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans. |
zacks.com |
2025-05-15 16:06:04 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results |
PALO ALTO, Calif. , May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025. |
prnewswire.com |
2025-05-14 20:15:00 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases |
PALO ALTO, Calif. , May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, Utah. |
prnewswire.com |
2025-05-02 03:43:00 |
Czytaj oryginał (ang.) |
| Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD) |
Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock. |
zacks.com |
2025-04-01 14:35:34 |
Czytaj oryginał (ang.) |
| Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus |
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans. |
zacks.com |
2025-03-28 12:46:10 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results |
PALO ALTO, Calif. , March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. |
prnewswire.com |
2025-03-27 18:01:00 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy |
Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026. GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significance PALO ALTO, Calif. |
prnewswire.com |
2025-03-10 18:39:00 |
Czytaj oryginał (ang.) |
| Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders |
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027. |
seekingalpha.com |
2025-02-23 22:08:22 |
Czytaj oryginał (ang.) |
| Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025 |
PALO ALTO, Calif. , Feb. 4, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA. |
prnewswire.com |
2025-02-04 09:30:00 |
Czytaj oryginał (ang.) |
| Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference |
PALO ALTO, Calif. , Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D. |
prnewswire.com |
2025-01-07 08:00:00 |
Czytaj oryginał (ang.) |
| KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates |
Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases. |
zacks.com |
2025-01-06 12:21:32 |
Czytaj oryginał (ang.) |
| What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 |
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025. |
zacks.com |
2024-12-26 13:32:08 |
Czytaj oryginał (ang.) |
| KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential |
Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications. |
zacks.com |
2024-12-10 13:45:47 |
Czytaj oryginał (ang.) |
| Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock |
Jefferies has upgraded Kodiak Sciences Inc. KOD, a biopharmaceutical company focused on retinal (eye) diseases. |
benzinga.com |
2024-12-09 14:33:39 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy? |
Kodiak Sciences Inc. (KOD) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KOD's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross. |
zacks.com |
2024-11-25 12:56:22 |
Czytaj oryginał (ang.) |
| Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus |
KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans. |
zacks.com |
2024-11-15 12:51:31 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results |
PALO ALTO, Calif. , Nov. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024. |
prnewswire.com |
2024-11-14 18:01:00 |
Czytaj oryginał (ang.) |
| Kodiak Sciences to Participate in Upcoming Investor Conferences |
PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences. |
prnewswire.com |
2024-11-11 08:15:00 |
Czytaj oryginał (ang.) |
| Kodiak Sciences to Present at Innovate Retina 2024 |
PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. |
prnewswire.com |
2024-10-14 21:35:00 |
Czytaj oryginał (ang.) |
| Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks |
KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications. |
zacks.com |
2024-10-10 15:06:28 |
Czytaj oryginał (ang.) |
| Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time |
NEW YORK , Sept. 23, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York. |
prnewswire.com |
2024-09-23 10:00:00 |
Czytaj oryginał (ang.) |
| Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City |
PALO ALTO, Calif. , Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. |
prnewswire.com |
2024-09-17 20:05:00 |
Czytaj oryginał (ang.) |
| Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report? |
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-09-13 16:31:06 |
Czytaj oryginał (ang.) |
| Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus |
Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans. |
zacks.com |
2024-08-16 15:45:51 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results |
PALO ALTO, Calif. , Aug. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended June 30, 2024. |
prnewswire.com |
2024-08-14 20:01:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Kodiak Sciences (KOD) Rating Upgrade to Buy |
Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-07-10 17:00:41 |
Czytaj oryginał (ang.) |
| Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio? |
Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications. |
zacks.com |
2024-06-20 13:25:22 |
Czytaj oryginał (ang.) |
| Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report? |
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-06-14 16:30:36 |
Czytaj oryginał (ang.) |
| Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences |
PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT), New York, New York Goldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT), Miami Beach, Florida A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events. |
prnewswire.com |
2024-05-29 20:36:00 |
Czytaj oryginał (ang.) |
| Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus |
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans. |
zacks.com |
2024-05-16 17:56:06 |
Czytaj oryginał (ang.) |
| Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results |
PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024. |
prnewswire.com |
2024-05-15 20:01:00 |
Czytaj oryginał (ang.) |